Company news
Candel Therapeutics, Inc. news in 2021
Candel Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.
Candel Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
November 11, 2021
Candel Therapeutics Presents Novel Biomarker Data Demonstrating Immune Activation After Administration of CAN-3110 in Patients with Recurrent High-Grade Glioma
November 11, 2021
Candel Therapeutics Announces Upcoming Data Presentations on its Oncolytic Viral Immunotherapies
October 31, 2021
Candel Therapeutics Announces Patient-Reported Tolerability Data of Intraprostatic Injections in Ongoing Phase 3 Clinical Trial of CAN-2409 in Patients with Localized Prostate Cancer
October 27, 2021
Candel Therapeutics Appoints Mace L. Rothenberg, MD, as Senior Advisor to the Chief Executive Officer
October 18, 2021
Candel Therapeutics Announces Participation in Upcoming Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
October 3, 2021
Candel Therapeutics Announces Participation in Upcoming Scientific Conferences Related to Oncolytic Viral Immunotherapies
September 30, 2021
Candel Therapeutics Announces Presentations of Key Clinical Data at AdMeTech and European Association of Neuro-Oncology Conferences in September 2021
September 8, 2021
Candel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Highlights
September 7, 2021
Candel Therapeutics Completes Enrollment in Phase 3 Clinical Trial of CAN-2409 in Combination with Valacyclovir for the Treatment of Intermediate-High Risk Localized Prostate Cancer
September 6, 2021
Candel Therapeutics Announces Closing of Initial Public Offering, Including the Partial Exercise of Underwriters’ Option
August 16, 2021
Candel Therapeutics Announces Pricing of Initial Public Offering
July 25, 2021